Navigation Links
KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
Date:12/22/2009

ST. LOUIS, Dec. 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company ( KVa/KVb) (the "Company") received permission from the New York Stock Exchange (the "Exchange") for its securities to continue to trade on the Exchange until March 31, 2010 while the Company prepares its Annual Report on Form 10-K for the Company's fiscal year ended March 31, 2009 (the "2009 Annual Report").

In the event the Company is unable to file the 2009 Annual Report on or prior to March 31, 2010, the Company may request that the Exchange permit the Company's securities to continue to trade on the Exchange until June 17, 2010. In the event the Company is unable to file the 2009 Annual Report prior to June 17, 2010 (or prior to March 31, 2010 in the event the Company requests that the Exchange permit the Company's security to continue to trade on the Exchange until June 17, 2010 and such request is not granted by the Exchange), the Exchange will initiate suspension and delisting procedures.

As previously disclosed by the Company on its Form 12b-25 filed with the SEC on June 2, 2009, as well as in subsequent filings with the SEC, the Company has been unable to file its 2009 Annual Report. The Company's Current Report on Form 8-K filed with the SEC on November 12, 2009 sets forth additional information regarding the Company's inability to timely file the 2009 Annual Report, certain other periodic reports, and related matters.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , , FRANKLIN LAKES, N.J., Jan. 11 ... announced today that it will conduct a live webcast of its ... 2010 at 10:00 a.m. (ET). BD will issue a press ... of the conference call, along with related slides, will be accessible ...
... Calif., Jan. 11 Finesse Solutions, LLC, a manufacturer ... applications, announced the production release of its single-use sensor ... and process temperature, and TruTorr headspace pressure sensors. ... ease of use. It is available on the Thermo ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2Single-Use Sensor Product Family Enters High Volume Production 2
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... Sudden Cardiac Arrest,Association (SCAA) has appointed Chris Chiames as ... Chris join SCAA as we begin to implement our,strategic ... our goal of,eliminating preventable sudden cardiac arrest deaths (SCA) ... SCAA Board of Directors.,"Advancements in medical technology and treatment ...
... Sept. 7 With safety issues making,headlines, ... rugged,regulatory landscape. Organizations are relying on their ... affect production. Proper,staffing of quality roles is ... and a study by pharmaceutical benchmarking leader ...
... Employees Start! Lacing Up Their Walking Shoes -, ... fight against sedentary lifestyles by participating in the,American ... promote,walking and other healthy habits in the workplace. ... a Start! "walkforce" team to,participate in today,s Wilmington ...
... BELLEVILLE, ON, Sept. 7 /PRNewswire-FirstCall/ - Bioniche ... Canadian,biopharmaceutical company, today announced that it has ... Economic Development (RED) Program of the,Ontario Ministry ... grant,announced by the Honourable Leona Dombrowsky, Minister ...
... be compromised by new provisions enabling commercial companies to ... , A study, led by the Centre for International ... that, as a result of changes to how ... to provide patients with integrated and comprehensive services. , ...
... This week, American Red,Cross President and CEO, Mark W. ... of Operations Support., In this role, Sean will ... and Diversity, Finance and Information Technology to,ensure optimal integration ... of business., "The Red Cross will benefit from ...
Cached Medicine News:Health News:Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association 2Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:AstraZeneca Leads Local Walking Movement 2Health News:AstraZeneca Leads Local Walking Movement 3Health News:AstraZeneca Leads Local Walking Movement 4Health News:Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine 2Health News:Care reforms raise concerns over patient access to GP services 2Health News:Sean P. McLaughlin Joins Red Cross as Chief of Operations Support 2
... on/off switch which allows user to stop rotor ... hinge, with stainless steel pin is virtually indestructible. ... Spins 6 microcentrifuge tubes at low to medium ... g. 6 inch x 6 inch footprint. Starts ...
Inquire...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... Powerful single rotation speed of 10,000 ... (x g) , Pellets single- and double-stranded ... and continuous spinning , 12-position rotor holds ... 1.5-ml microcentrifuge tubes , Replaceable rotor ...
Medicine Products: